• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Some Antidepressants May Help Longer Than Others
Research Update

Some Antidepressants May Help Longer Than Others

April 1, 2025
Jeremy Mills, DNP, PMHNP-BC
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

 Jeremy Mills, DNP, PMHNP-BC. Dr. Mills has no financial relationships with companies related to this material.

Getting your Trinity Audio player ready...

REVIEW OF: Kessing LV et al, Acta Psychiatr Scand 2024;149(5):378–388

STUDY TYPE: Retrospective cohort

Choosing an antidepressant for major depressive disorder often requires our best educated guesses. While we have short-term data, longer-term outcomes are less clear. 

Kessing et al addressed this by analyzing antidepressant prescriptions for over 100,000 Danish adults with a first diagnosis of depression from 1995 to 2018. They tracked nonresponse, defined as switching, augmenting, or hospitalization. Patients on multiple first-line meds were excluded. The researchers used a “target trial” design to mimic RCTs, comparing drugs within the same class and adjusting for variables like age, sex, employment, and some comorbidities. In the results below, note that relative risk (RR) refers to how much more (or less) likely a certain outcome is with one treatment compared to another. An RR of 1.13, for instance, means there’s a 13% greater chance of nonresponse compared to the reference medication. 

Results
Among selective serotonin reuptake inhibitors (SSRIs), sertraline marginally outperformed escitalopram (RR: 1.22), fluoxetine (RR: 1.13), and paroxetine (RR: 1.06), but was similar to citalopram.

Among serotonin/norepinephrine reuptake inhibitors (SNRIs), ­venlafaxine slightly outperformed duloxetine (RR: 1.04).

Among tricyclic antidepressants (TCAs), amitriptyline did better than clomipramine (RR: 1.20) and nortriptyline (RR: 1.15).

In the “other” category, sertraline outperformed vortioxetine (RR: 1.15).

CARLAT TAKE
This study was observational, involved a Danish cohort, and relied solely on prescription data. It did not examine side effects, response rates, symptom severity, or the reasons for changing or augmenting medications. The differences between antidepressants were also not very pronounced. That said, when all other things are equal, these findings support sertraline and citalopram among SSRIs, venlafaxine among SNRIs, and amitriptyline among TCAs for long-term treatment of depression.

General Psychiatry
KEYWORDS antidepressant citalopram research update sertraline
    Jeremy Mills, DNP, PMHNP-BC

    Cariprazine Augmentation for MDD

    More from this author
    www.thecarlatreport.com
    Issue Date: April 1, 2025
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Stimulant Prescribing, TCPR, April 2025
    New Weight Loss Drugs in Psychiatry
    ADHD, Stimulants, and Substance Use
    Some Antidepressants May Help Longer Than Others
    CME Post-Test, Stimulant Prescribing, TCPR, April 2025
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2637648401.jpg
      General Psychiatry

      Psychopharm Secrets: Coming Off Meds

      There’s a hidden placebo response to watch for when patients stop meds on their own.
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.